BioTech

We explore which cell therapy, genetic editing and other innovative technologies are democratizing access to and costs of healthcare, and enabling better quality of life. 

The Specter of Theranos Is Haunting Biotech Startups

The final chapter in Elizabeth Holmes’ story as an entrepreneur is set to begin next year with her fraud trial scheduled for summer of 2020. But medical device startups and investors may find the fallout from the crash and burn of her...

Microbiome Experts Call Out Technology’s Limits, Saying it’s Still Early Days of Personalized Medicine

Karma_News Analysis_probiotics
While the number of microbiome-focused products and investments rises, the science remains in a nascent stage, and expectations for the industry may be ahead of reality, according to speakers at a Bard College symposium on Thursday. Martha Carlin, CEO...

Startups Using Agility, Experience, to Move the Needle on Opioid Crisis

From a social network for addicts to robots that test sewage water for traces of drugs, startups and private companies are applying innovative solutions to one of the nation’s most pressing problems -- its opioid epidemic. Over 11.4 million people have misused...

Biotech Epirium Raises $85M With Aim to Develop Anti-aging Technology

Karma_News Summary_anti-aging
It may be the final frontier in medicine -- slowing down or reversing the process of aging. Besides the promise of a longer life, it also means fortunes made -- think Ponce de Leon and his search for the Fountain of Youth.

FDA Warns Medical Devices May Be Vulnerable to Hackers, Highlighting Vulnerability of Equipment to Attacks

Karma_News Analysis_Medical device cybersecurity
Pacemakers, insulin pumps and other medical devices using software called IPnet contain potential flaws that make them vulnerable to cyber attacks, the Food and Drug Administration has warned.The agency is working with medical device makers to determine which devices, whether in health-care...

FDA Will Consider Biogen’s Controversial Drug as First New Alzheimer’s Treatment Drug in 17 Years

Karma_News Summary_Alzheimer's treatment
A controversial drug that treats the early stages of Alzheimer’s disease might become the first medication for the disease in 17 years to win regulatory approval. Biogen Inc. said it plans to submit a regulatory filing for its aducanumab...

Musk’s Neuralink Promises Innovation But Requires Trust and Proof

While Elon Musk’s brain implant company, Neuralink, has announced plans to begin human patient tests before the end of next year, experts believe proving the technology’s competence may take longer. In an event yesterday, held primarily for recruiting more...

“New Era for Quantum Biology” Is Upon Us

Karma_News Summary_Quantum biology
It has been an exciting week for quantum biology enthusiasts, with two separate studies suggesting new ways to leverage quantum principles in life sciences applications. Researchers from the Quantum Nanophysics Group at the University of Vienna found a “quantum...

Nebula Genomics Puts DNA on Blockchain to Buoy Privacy-Concerned Consumers

Karma_Profile_Nebula
Key Takeaway: With concerns about the privacy of genetic data rising, Nebula Genomics has developed a Blockchain-based genomic marketplace, where users decide who gets access to their data and potentially receive compensation...

Brave New World: Investors Bet $100 Million on Success of Pig-to-Human Organ Transplants

Karma_News Summary_eGenesis
The transplantation of pig organs into humans moved a step closer to reality after investors upped their bets, pouring in $100 million, on the work of biotechnology company eGenesis. The Cambridge, Massachusetts company uses new gene-editing technologies to make...

Novartis $2M Drug For Killer Genetic Disease to Be Dispensed for Free Via Lottery

Karma_News Summary_Novartis
It’s the world’s most expensive drug, and one of only two available for spinal muscular atrophy, the top genetic killer of children under two years old. And now the drug’s maker, Novartis, wants to give it away using a procedure considered controversial...

Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model

Karma_News Summary_Heart in a Jar
Stem cell biotech company Novoheart and pharmaceutical giant AstraZeneca announced they would be partnering to develop the first test tube model of human heart failure, also called heart-in-a-jar. The companies said they would use heart tissue engineered by Novoheart...

Researchers Use Gene Modification to Defeat Rice-Killing Disease

Karma_News Summary_CRISPR
Researchers successfully edited the genome of strains of rice grown in Southeast Asia and West Africa to block a pathogen that ravages yields of the staple crop, the latest example of gene modification that may reduce hunger throughout the world.Bacterial blight is...

Despite Concerns About Gene Editing, Venture Investors, Big Pharma Remain a Captive Audience

Karma_News Summary_Gene Editing Big Pharma
A year after a Chinese scientist unleashed a storm of condemnation by announcing the birth of a baby whose genes he had edited, the medical and scientific community has yet to agree on rules guiding research into the practice.

GHO Capital, Spying European Healthcare Opportunities, Raises Record Fund

Karma_News Summary_GHO Capital
Private equity firm GHO Capital Partners, reflecting European investors’ bullishness for healthcare, topped expectations by raising almost $1.1 billion for its second fund.  The total, surpassing GHO’s $885 million goal, is a record for a fund targeting European healthcare,...

How Mark Zuckerberg Wants to Fix Science

Karma_News Analysis_Facebook Healthcare
Mark Zuckerberg, Facebook’s embattled co-founder and CEO, isn’t just interested in creating the biggest ad machine and political platform in history. He also wants to fix and accelerate the rate of scientific discovery. In a video conversation published on...

Japan Set to Create Hybrid Mammal for Organ Donation, Unleash Ethical Storm

In a move certain to set medical ethicists’ heads spinning, stem-cell researchers in Japan are launching a study with an aim to create hybrid animals out of rats and mice that will produce human organs for medical transplant, according to media reports.

Creating Health’s Future: 5,000+ Leading Health Executives to Converge at HLTH 2019

HLTH
This content is brought to you in partnership with HLTH. How do we create the future of health? That’s the question HLTH is seeking to answer.  From Oct. 27-30, more than 5,000 executives, investors and entrepreneurs...

U.S. Wants More Domestic Pharma Production as Quality Concerns Persist; Lawmakers Worry About China’s Power

Karma_News Summary_Pharmaceuticals
As concerns rise about the growing percentage of U.S. drugs manufactured in China, U.S legislators are seeking measures to bring more of the industry back onshore. During a congressional hearing Wednesday, regulators and lawmakers in both parties expressed interest...

Biotech Startup Is Vying to Improve Memory Through Brain Implants

If Nia Therapeutics succeeds, brain chips will enter medical clinics in three years that will  provide memory generation for all patients suffering from brain injuries or disorders. Michael Kahana, a University of Pennsylvania researcher, and Dan Rizzuto, a neuroscientist,...

MEND Aims for Untapped Market: Better Nutrition for Surgery Patients

Life sciences start-up MEND believes better nutrition will help concussion patients before and after surgery, and is seeking to roll out another of its supplement powders to tap that market. The New York company is filing a patent for...

Biotech Achilles Raises $120 Million For Trials of Immune System-Harnessing Cancer Drugs

Secondary lung cancer, light micrograph
Achilles Therapeutics’s raising of $120 million to conduct clinical trials of a cancer treatment underscores the promise of therapies that use immune systems to target and eradicate tumor cells. The Achilles therapy uses a unique T-cell, a type of...

Bristol-Myers Partners with Accelerator BioMotiv to Develop New Drugs

test tube close up
Pharmaceutical giant Bristol-Myers Squibb will become a limited partner in BioMotiv, a Cleveland-based biotech accelerator, to jointly fund new research into therapies in disease areas with unmet medical needs.  “Partnering with an innovative accelerator like BioMotiv strengthens our ability...

Russian Scientist Plans Gene-Edited Baby Following Chinese Experiment

On Our Radar: Deals we are paying attention to, for their impact on industry Russian scientist Denis Rebrikov told Nature he’s planning the same experiment a Chinese scientist did last year that the rest of the world is more...

Biotech Startup Luca Mines Women’s Biome Data to Treat UT Infections, Other Health Issues

When Luca Biologics began operations this spring, it was a startup in name only, since its co-founders had been collecting laboratory data on women’s health for nearly two decades.  Armed with that research, Luca is ready to develop biotherapies...

Johns Hopkins to Expand Psychedelics-As-Medicine Research With $17 Million Center

large magic mushroom
Magic mushrooms as treatment for depression, PTSD other issues is getting a major boost at Johns Hopkins University, as researchers continue efforts, sometimes backed by venture capital, to find therapies in alternative, overlooked places. Johns Hopkins, which has been...

Private Equity, Biotech Industry Worried Pelosi Drug Plan Would Be ‘Destructive,’ Slow Innovation

Karma_News Summary_Pelosi drug plan
Private equity and venture capital firms, which have poured billions of dollars in biotech firms, are opposing House Speaker Nancy Pelosi’s plan to cut drug prices, saying it would stifle the small firms that are often the source of new medications.

Magic Mushrooms Move Closer to Mainstream Medicine As VC-Backed Compass Touts Safety, “Positive Mood Alteration”

Karma_News Summary_Magic mushrooms
Magic mushrooms as a treatment for depression took another step toward mainstream acceptance as a venture capital-backed company announced positive results from a psilocybin trial. Compass Pathways’ psilocybin medication was “well-tolerated in healthy volunteers,” a first step in seeking...

Blackstone Teams With Swiss Firm Ferring For $570 Million Effort to Make Cancer Killing Gene Therapy

Karma_News Summary_Blackstone invests in Ferring
Blackstone, which last year started up a life sciences investing arm, is pouring $400 million into a venture with a Swiss pharmaceutical firm to develop and commercialize a gene therapy for bladder cancer. Blackstone’s investment seeks to spur FerGene,...

Ancestry’s IPO Talk Shows How Consumer DNA Testing Has Matured

Surging popularity of home DNA kits that enable consumers to uncover secrets of their ancestry and health risks has fueled speculation that the industry is set for further disruption this year. Ancestry.com, the world’s largest direct-to-consumer genetic-testing company, is getting ready for an initial public...
- Advertisement -